Positive news from the dose escalation stage would theoretically speed up the recruitment for the efficacy stage for the Sheba trial. Note - this trial excludes Extramedullary patients.
The combination in the Australian trial that is set to start soon is different to the combination in the Sheba trial. This trial is focused on patients with Extramedullary AML or high-risk MDS.
The indications for the two trials are different and hence the patient selection criteria are different.
Ann: Trading Halt, page-37
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.45 |
Change
0.025(1.76%) |
Mkt cap ! $242.0M | |||
| Open | High | Low | Value | Volume |
| $1.43 | $1.45 | $1.40 | $107.5K | 75.98K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 12711 | $1.41 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.45 | 1250 | 1 |
View Market Depth
| Last trade - 12.34pm 15/11/2024 (20 minute delay) ? |
| RAC (ASX) Chart |